AI-Designed Drug Shows Promise in Reversing Biological Age in Clinical Study

An AI-designed drug candidate, rentosertib, reversed biological age by at least three years in a small Phase 2a clinical trial, according to a new study.

Plain English

Scientists at Insilico Medicine used artificial intelligence to design a drug originally meant to treat a lung-scarring disease. When they tested it on 42 patients over 12 weeks, they used a new method called "proteomic aging clocks" to measure biological age. The results showed the drug made...